Joseph A. November is an Associate Professor in the Department of History at the University of South Carolina, affiliated with the McCausland College of Arts and Sciences. His research focuses on the history of biomedical computing, distributed computing, and the intersection of technology and medicine. He holds a Ph.D. from Princeton University (2006), an M.A. from the University of Chicago (2002), and a B.A. from Hamilton College (1997). His work includes the award-winning book Biomedical Computing: Digitizing Life in the United States (2012), which explores the co-development of biomedicine and computing technologies. Current projects include Revolutions@home , examining distributed computing in protein folding research, and a biography of computing pioneer Robert S. Ledley. He has received grants from the NSF, NIH, and the Charles Babbage Institute. Teaching interests span the history of science and technology, including courses on the history of medicine, digital humanities, and the role of games in historical education. He actively contributes to professional organizations like SHOT and the History of Science Society. Awards include the Computer History Museum Prize (2013) and the National Institutes of Health DeWitt Stetten Fellowship (2007-2008). His research bridges historical analysis with contemporary issues in technology and biomedical ethics.
Didier Trono is a Full Professor at École Polytechnique Fédérale de Lausanne (EPFL), where he leads the Laboratory of Virology and Genetics (LVG) within the School of Life Sciences. Formerly, from 2004 to 2012, he served as the founding dean of EPFL's Faculty of Life Sciences, orchestrating its development and growth during this formative period. Trono received his medical education at the University of Geneva, followed by clinical training in pathology, internal medicine, and infectious diseases in Geneva and at Massachusetts General Hospital in Boston. His scientific career began at the Whitehead Institute of MIT, and in 1990 he was recruited by the Salk Institute of San Diego to launch an AIDS research center. After seven years in the United States, he returned to Europe and eventually joined EPFL. Dr. Trono's research has evolved significantly over his career. Initially focusing on virus-host interactions, he studied pathogens like HIV and Hepatitis B virus, creating HIV-derived genetic transfer tools that are now successfully used in gene therapy. For approximately the last fifteen years, his research has centered on epigenetics, particularly exploring the impact of retroelements and their control mechanisms on development and physiology of higher organisms, including humans. His laboratory investigates how transposable elements and KRAB zinc finger proteins regulate gene expression, with important implications for understanding cancer biology and developing new diagnostic and therapeutic approaches. Analysis of his recent publications (2022-2024) reveals a strong focus on transposable elements, KRAB zinc finger proteins, and their roles in gene regulation and cancer. His work combines molecular biology, genomics, and bioinformatics approaches to understand how these ancient viral remnants have been co-opted by the host genome to regulate development and cellular functions. The research spans basic molecular mechanisms to potential clinical applications in cancer diagnosis and therapy, with some recent work also addressing SARS-CoV-2 and immune responses. Throughout his career, Professor Trono has mentored numerous PhD students, including Bojkowska Karolina, Brandão Sanches Vong Martins Filipe Amândio, Bulliard Yannick, Coluccio Andrea, Corsinotti Andrea, Coudray Alexandre, De Tribolet-Hardy Jonas Caspar, and Dorschel Iris Arianna. His laboratory has received significant funding to support research at the intersection of virology, genetics, and epigenetics, contributing to EPFL's reputation as a leading institution in life sciences research. The Trono Laboratory continues to be at the forefront of research on retroelements and their regulatory mechanisms, maintaining a vibrant research environment that bridges fundamental biological questions with potential medical applications, particularly in cancer research and precision medicine.
Rolf Halden is a Professor and Center Director at Arizona State University, holding appointments in the School of Sustainable Engineering and the Built Environment, the Biodesign Center for Environmental Health Engineering, and the Global Futures Scientists and Scholars program. He is a leading expert in environmental health engineering, wastewater-based epidemiology, and bioremediation. Education: Ph.D. in Civil (Environmental) Engineering, University of Minnesota (1997) M.S. in Civil (Environmental) Engineering, University of Minnesota (1994) M.S. in Biology, Technical University of Braunschweig, Germany (1992) Postdoctoral Fellow, Environmental Science, Lawrence Livermore National Laboratory (1998) Research Focus: Halden’s research integrates environmental chemistry, public health, and sustainability to understand how anthropogenic chemicals affect ecological and human health. His lab uses advanced mass spectrometry (LC-MS/MS, MALDI-TOF) to track pollutants such as PPCPs, microplastics, pesticides, and dioxins across air, water, soil, and biological systems. He pioneered the use of wastewater treatment plants as public health observatories, enabling real-time tracking of disease, drug use, and environmental exposures. Scientific Awards & Recognition: Leadership Award, Arizona State University (2018) Rocky Mountain Emmy Award (2018) Leroy E. Burney Lecturer, Johns Hopkins School of Public Health (2011) ACS Expert Program Member (2014–present) NIEHS Superfund R01 Working Group National Leader (2012–2014) Labs & Teams: Halden is the Founding Director of the Biodesign Center for Environmental Health Engineering at ASU, where he leads a multidisciplinary team focused on environmental proteomics, bioremediation, and diagnostic tool development. He also co-leads the Human Health Observatory , a national wastewater monitoring network. Grants & Funding: Halden has secured major funding from NSF, NIH, EPA, DoD, and private industry. Notable projects include the development of in-situ groundwater monitoring devices, national wastewater surveillance of SARS-CoV-2, and studies on microplastics and neurodegenerative disease.
David Erickson is the SC Thomas Sze Director and Sibley College Professor at Cornell University's Sibley School of Mechanical and Aerospace Engineering. He also holds a joint professorship in the Division of Nutritional Sciences. His research focuses on global health technologies, medical diagnostics, microfluidics, photonics, nanotechnology, and energy systems. He previously served as Associate Dean of Engineering for Research and Graduate Programs. Erickson leads the NIH-funded PORTENT Center for Point-of-Care Technologies in Global Health and has co-founded companies like Dimensional Energy and VitaScan to commercialize diagnostic and energy technologies. Education: B.Sc., Mechanical Engineering, University of Alberta (1999) M.A.Sc., Mechanical Engineering, University of Toronto (2001) Ph.D., Mechanical Engineering, University of Toronto (2004) Postdoctoral Scholar, Electrical Engineering, California Institute of Technology (2005) Research Interests: Erickson’s work spans global health diagnostics , nanobio applications , and clean energy innovation . He develops portable medical devices for low-resource settings, including smartphone-integrated diagnostic tools for malaria, iron deficiency, and cancer. His lab also pioneers photothermal reactors for CO2 conversion into sustainable fuels. Key areas include: Point-of-care testing for infectious diseases and nutritional deficiencies Nanofluidic and optofluidic technologies for biomolecular analysis Solar-driven energy systems for carbon-neutral fuels Awards: Presidential Early Career Award for Scientists and Engineers (2011) Fellowships from the Optical Society, ASME, and Canadian Academy of Engineering Carbon X-Prize Finalist (2019) for Dimensional Energy’s CO2-to-fuel technology Grants & Industry Collaboration: Erickson’s research is funded by NIH, NSF, ARPA-E, DOE, and USAID. His lab’s innovations have spun off start-ups addressing global health and energy challenges. Notable projects include: - Portable cancer diagnostics in sub-Saharan Africa using mobile phone-based systems - Solar-powered CO2 conversion reactors tested in Wyoming and Arizona Labs & Teams: The Erickson Lab collaborates with the Cornell Atkinson Center for Sustainability and the McGovern Center for Entrepreneurship. Key initiatives include the PORTENT Center and the Dimensional Energy CO2-to-fuel project.
Dr. Vakil Takhaveev is a Lecturer at ETH Zurich's Department of Health Sciences and Technology, within the Institute of Food, Nutrition and Health. His research focuses on DNA damage mechanisms, aging, cancer, and neurodegeneration, with particular emphasis on developing novel DNA-damage-sequencing methods like click-code-seq and TRABI-Seq . He investigates anticancer drug action (e.g., trabectedin), aging clocks using DNA oxidation profiling, and stress-induced carcinogenesis. His work integrates multi-omics approaches and advanced sequencing techniques. Research Directions: Novel DNA-Damage-Sequencing Methods: Developed click-code-seq and TRABI-Seq for genomic mapping of DNA lesions and repair dynamics. Anticancer Drug Action: Explored mechanisms of trabectedin and other chemotherapeutics, linking DNA repair vulnerabilities to therapy resistance. Aging Clocks: Created DNA oxidation-based biomarkers for biological aging using genome-wide profiling in human and mouse models. Stress-Induced Pathologies: Studies metabolic and DNA damage links to early tumorigenesis and neurodegeneration. Awards & Recognition: 2025 Public Award Winner in PIs of Tomorrow competition 2024 ETH Zurich Career Seed Award Best presentation awards (Swiss Chemical Society, American Chemical Society) Grants & Collaborations: Impetus grants for aging clock development Swiss Chemical Society and American Chemical Society fellowships Labs & Teams: Leads research on DNA damage and aging mechanisms at ETH Zurich, collaborating with international groups in oncology and toxicology.
John D Brennan is a Professor in the Department of Chemistry & Chemical Biology at McMaster University. He is affiliated with the Biointerfaces Institute and focuses on developing innovative biosensing technologies and functional nucleic acid-based assays. His research integrates materials science, biochemistry, and analytical chemistry to create practical diagnostic tools for healthcare applications. Key research areas include the design of DNA aptamers and DNAzymes for detecting biomarkers (e.g., eosinophil peroxidase, SARS-CoV-2 spike proteins), development of paper-based diagnostic platforms, and optimization of sol-gel materials for enzyme entrapment. His work emphasizes high-throughput screening, point-of-care testing, and CRISPR-based biosensing systems. Notable contributions include a rapid sputum-based assay for asthma biomarkers and a universal DNA aptamer for SARS-CoV-2 variants. His lab also explores functional nucleic acid circuits and their integration into scalable diagnostic devices. Brennan’s teaching includes advanced courses in analytical chemistry and biochemical assay development. His work has been featured in journals like *Angewandte Chemie*, *Analytical Chemistry*, and *ChemBioChem*, with a focus on translating fundamental research into practical clinical applications.
Assoc Prof Ng Teng Yong is an Associate Professor at the School of Mechanical & Aerospace Engineering (NTU), specializing in numerical modeling and simulation. With a background as Research Manager at A*STAR Institute of High Performance Computing, his work spans materials science, nanotechnology, and aerospace engineering. Current focus on graphene-based desalination membranes Expertise in molecular dynamics simulations Investigates nanoscale fluid mechanics and structural dynamics Recent publications highlight advancements in energy-efficient electrodialysis, smart robotics, and nonlinear vibration analysis. His interdisciplinary approach integrates computational methods with experimental validation in additive manufacturing and soft material mechanics.
Karan S Dixit, MD is an Assistant Professor in the Department of Neurology at Northwestern University's Feinberg School of Medicine, specializing in neuro-oncology and serving as Fellowship Director for the education program. His educational background includes: MD from Louisiana State University (2011) Internal Medicine Internship at University of Illinois at Chicago (2012) Neurology Residency and Chief Medical Resident at University of Illinois at Chicago (2015) Neuro-Oncology Fellowship at Northwestern University McGaw Medical Center (2016) He maintains board certification in Neurology (American Board of Psychiatry and Neurology) and Neuro-Oncology (United Council for Neurologic Subspecialties). Dr. Dixit's research centers on CNS lymphoma, lower-grade gliomas, and glioblastoma, with emphasis on novel therapies for treatment resistance. He investigates biomarkers for disease monitoring and explores neurocognitive decline mechanisms related to neural connectivity changes during CNS cancer treatment. His work bridges clinical neurology with translational oncology through molecular diagnostics and therapeutic innovation. His 2025 publications reveal three critical research trajectories: molecular characterization of glioma mutations (TERT/IDH), liquid biopsy applications for CNS lymphoma diagnosis, and repurposing antiseizure drugs with antineoplastic potential. These studies collectively advance precision medicine approaches for treatment-resistant CNS malignancies. Professional recognition includes: John A Kessler Teaching Award (2022, 2019) NeuroNEXT Fellow (2020) Society of Neuro-Oncology Clinical Trials Course (2019) University of Illinois Teaching Excellence Awards (2014-2015) As Fellowship Director, Dr. Dixit mentors neuro-oncology trainees while leading three active clinical trials: Vorasidenib/Pembrolizumab for IDH-mutant glioma (NCT05484622), NX-5948 BTK degrader for CNS lymphoma (NCT05131022), and emavusertib for relapsed PCNSL (NCT03328078). His industry collaborations include Bluprint Oncology Concepts and Servier Pharmaceuticals for therapeutic development. He maintains active membership in the Feinberg Academy of Medical Educators, American Neurological Association, American Academy of Neurology (Neuro-Oncology Section), American Society of Clinical Oncology, and Society of Neuro-Oncology, collaborating through Northwestern Medicine's Robert H. Lurie Comprehensive Cancer Center and Clinical and Translational Sciences Institute.
Jennifer L. Clarke is a Professor in the Department of Statistics at the University of Nebraska–Lincoln and Director of the Quantitative Life Science Initiative. She holds leadership roles in enabling big data integration across the University of Nebraska system through collaborative research programs. Her affiliations include the Institute of Agriculture and Natural Resources (IANR) and the College of Agriculture and Natural Resources. Dr. Clarke's research focuses on statistical methodology for high-dimensional data, computational biology, bioinformatics, and bacterial genomics. Her work bridges statistical innovation with applications in oncology, microbiome analysis, and agricultural phenomics. Key areas include predictive modeling, machine learning, and genomic/metagenomic data integration. Her recent publications span cancer biomarker discovery, plant phenotyping methodologies, and microbial community analysis, reflecting her interdisciplinary approach. Articles emphasize translational applications like therapeutic target identification and precision agriculture. Dr. Clarke leads initiatives fostering collaboration between statisticians and domain scientists, including the Quantitative Life Science Initiative and contributions to the Agricultural Genome-to-Phenome Initiative (AG2PI). Her work advances data-driven solutions for healthcare and food security challenges. Notable projects include developing statistical tools for microbiome studies, analyzing root architecture via 3D imaging, and investigating cranberry-derived compounds' cancer-inhibitory mechanisms. Her methodological contributions include hybrid clustering techniques and predictive model validation frameworks.
Associate Professor Anna Waterhouse is a Robinson Fellow and Head of the Cardiovascular Medical Devices Group at the Charles Perkins Centre, School of Medical Sciences, University of Sydney. Her research focuses on developing antithrombogenic materials and bioinspired medical devices to address cardiovascular diseases. She holds affiliations with the University of Sydney Nano Institute and the Australiasian Society for Biomaterials and Tissue Engineering as Treasurer and Secretary. Education includes a BSc (1st class hons) in Cell Biology from the University of Manchester and a PhD in bioengineering from the University of Sydney. She completed postdoctoral training at Harvard University’s Wyss Institute. Research interests span biomaterials, thrombosis prevention, and medical device engineering. Key projects include liquid-infused surfaces for anti-thrombotic coatings and biomimetic in vitro models. Her work integrates bioengineering, nanotechnology, and surface modification to improve medical device compatibility. Scientific awards include the Robinson Fellowship and CPC Mid-Career Researcher Support Award. Grants funded by ARC, Heart Foundation, and NSW Health support projects like slippery nano-coatings for medical devices. She advises PhD students in biomolecular nanotechnology, endothelial cell studies, and DNA nanostructures. Labs and collaborations involve Sydney Nano Institute and Charles Perkins Centre, focusing on translational research in cardiovascular and biomedical engineering.
Matthew Lakin is an Associate Professor with tenure in the Department of Computer Science at the University of New Mexico, with a courtesy appointment in the Department of Chemical & Biological Engineering. He is affiliated with the UNM Center for Biomedical Engineering and the School of Engineering, and collaborates extensively with the UNM Health Sciences Center and external institutions. Education: Ph.D., Computer Science, University of Cambridge, 2010 M.A. (Cantab), University of Cambridge, 2009 B.A. (Hons), Computer Science, University of Cambridge, 2005 Dr. Lakin's research focuses on molecular computing, DNA nanotechnology, synthetic biology, and formal verification of biomolecular circuits. He develops computational models and experimental systems for programmable biological devices, especially using heterochiral DNA to enhance stability in living cells. His work spans software tools for biodesign and experimental validation in mammalian systems, with applications in nanomedicine and biosensing. The recent publications highlight a strong trend in engineering robust, intelligent biomolecular systems. His work integrates machine learning concepts into chemical reaction networks, advances geometric modeling of DNA systems, and pioneers L-DNA-based circuits for intracellular applications. The research spans theoretical foundations, software tools, and wet-lab experimentation, emphasizing interdisciplinary innovation. Scientific Awards: Presidential Early Career Award for Scientists and Engineers (PECASE), 2025 NSF CAREER Award, 2021 UNM School of Engineering Junior Faculty Research Excellence Award, 2021 Multiple student awards under his mentorship, including the Outstanding Graduate Student Award and DNA28 Best Student Presentation recognition Dr. Lakin has advised numerous graduate and undergraduate students, including Ph.D. graduates in Biomedical Engineering and Computer Science. He leads major funded projects such as the NSF CAREER grant on heterochiral molecular computing, an EPSCoR Research Fellowship, and a $3M NSF grant on heavy metal biosensing in collaboration with Native American communities. He is also PI on multiple NSF grants related to synthetic cells and nucleic acid technologies. He directs the Lakin Lab for Programmable Biology, which operates within the Department of Computer Science and collaborates with Chemical & Biological Engineering and the Center for Biomedical Engineering. The lab emphasizes both computational modeling and experimental molecular biology, and runs an NSF-funded biotechnology summer camp in partnership with ¡Explora! science museum to strengthen STEM education in New Mexico.
Dr. Daniel Roxbury is an Associate Professor and Graduate Director at the Department of Chemical, Biomolecular and Materials Engineering within the University of Rhode Island's College of Engineering. With expertise in nanoscience and carbon nanomaterials, his research focuses on nano-bio interactions, developing functionalized nanotubes for biomedical applications and environmental monitoring through his NanoBio Engineering Laboratory. His work spans multiple disciplines including: Biomedical nanosensors Smart wearable biomaterials Targeted drug delivery systems Environmental nanotechnology Single-molecule imaging Nanotoxicology Recent publications emphasize machine learning-enhanced spectral analysis, coral reef conservation nanotechnology, and wearable stress monitoring textiles. His 2024 ACS Nano study introduces AI-driven macrophage phenotyping, while 2023 Nature Nanotechnology work explores coral reef restoration strategies using nanomaterials. Awarded the 2019 NSF CAREER grant for cellular nanometrology, he leads multiple NIH-funded projects including: $820,000 NSF CAREER: Spectral Imaging for Sub-Cellular Nanometrology $140,000 Miriam Hospital COBRE: Cortisol Detection Textiles $700,000 NSF EAGER: Multiplexed Wound Biomarker Detection His laboratory houses state-of-the-art equipment including: Near Infrared Hyperspectral Microscope Custom NIR Fluorescence Spectrometer Jasco UV/VIS/NIR Spectrophotometer Biosafety Cabinet Cell Culture Incubator Cryo-Storage System
Dr. John A. Copland III is a Professor of Cancer Biology and Biochemistry & Molecular Biology at Mayo Clinic in Jacksonville, Florida. He leads the Cancer Biology and Translational Research Laboratory, focusing on molecular mechanisms of carcinogenesis, tumor progression, and development of targeted cancer therapies. Education: PhD in Physiology & Endocrinology (Medical College of Georgia), MS in Endocrinology (Medical College of Georgia), BS in Chemistry (Columbus College), with postdoctoral training at University of Texas Medical Branch. Research interests center on: Identifying tumor suppressor genes (e.g., RhoB, TBR3, GATA3) and oncogenes (e.g., FOXO3a, SCD1, NPTX2). Developing patient-derived xenografts and live cell models for personalized medicine. Designing SCD1 inhibitors via in silico modeling for clinical trials. Recent publications highlight his work on SCD1 inhibition in leukemia and thyroid cancer ImmunoPET imaging of thyroid tumors CRISPR-identified drug synergies in cholangiocarcinoma Patient-specific combination therapies using xenograft models
Ruth Etzioni is an Affiliate Professor in the Biostatistics Program and Public Health Sciences Division at the Fred Hutchinson Cancer Center. She leads the Etzioni Lab, focusing on cancer screening, early detection, and overdiagnosis analysis. Her work integrates statistical modeling, epidemiology, and clinical research to address critical questions in prostate and breast cancer control. Dr. Etzioni holds the Rosalie & Harold Rea Brown Endowed Chair and has received a $7.4M NIH Outstanding Investigator Award. Education: PhD in Statistics (Carnegie Mellon University, 1990), MS in Statistics (Carnegie Mellon, 1987), BS in Mathematics (University of Cape Town, South Africa). Research interests emphasize biomarkers, clinical trials, and epidemiological methods. She leads the Biostatistics Core for the Pacific Northwest Prostate Cancer SPORE and participates in the Cancer Intervention and Surveillance Modeling Network (CISNET). Her lab develops models to evaluate screening policies, quantify overdiagnosis, and inform healthcare disparities reduction strategies. Key achievements include groundbreaking work on prostate cancer screening's harm-benefit tradeoffs and contributions to multi-cancer early detection (MCED) frameworks. Recent studies address racial disparities in prostate cancer outcomes, metastasis trends, and the clinical utility of novel diagnostics like PSMA PET imaging. Awards include the Brown Endowed Chair (2020), NCI OIA Award (2023), and recognition for advancing cancer data science. Her lab collaborates with institutions globally and mentors students in biostatistics and translational data science.
Professor Marek Sanak serves as Full Professor at the Department of Internal Medicine, Jagiellonian University Medical College in Cracow, Poland. He concurrently holds leadership positions as Acting Director of the Department of Forensic Medicine, Head of the Division of Molecular Biology and Clinical Genetics, and Vice-Rector for Research and International Cooperation since 2016. His academic foundation includes: MD from Jagiellonian University Medical College Specialization in Pediatrics and Genetics PhD from Jagiellonian University Research appointments at Harvard University, University of Paris VI, and University of Zurich Professor Sanak's research integrates clinical genetics with molecular immunology, focusing on asthma pathogenesis, lipid mediators of inflammation, and genetic diagnostics. His laboratory employs advanced techniques including deep DNA/RNA sequencing to identify biomarkers and elucidate disease mechanisms. The work bridges fundamental molecular discoveries with clinical applications in respiratory diseases, allergic disorders, and forensic medicine, demonstrating particular expertise in aspirin-exacerbated respiratory disease and epigenetic regulation of inflammatory pathways. Analysis of his recent publications reveals a strategic evolution from classical asthma research toward molecular genetics and viral pathogenesis. His 2017-2021 work increasingly incorporates epigenetic approaches (DNA methylation, microRNA profiling) while expanding into SARS-CoV-2 research during the pandemic. The publications demonstrate interdisciplinary integration across immunology, respiratory medicine, and molecular diagnostics, with consistent focus on translational applications. His distinguished career has been recognized through numerous honors: The Lancet Investigators Award on Asthma (1997) Polish Ministry of Health Individual Prize (1999) Jagiellonian Laurel (2012) Pro Arte Docendi Award (2014/15) Gold Medal for Long Service (2019) Top 2% of world scientists ranking (Elsevier 2022) As Vice-Rector for Research, Professor Sanak has significantly expanded international collaborations with King's College London, University of Southampton, and University of Zurich. His leadership has secured substantial funding for molecular diagnostics and inflammatory disease research while mentoring numerous early-career researchers. He delivers invited lectures globally for organizations including the American Thoracic Society and European Academy of Allergy and Clinical Immunology. Professor Sanak directs integrated research units across the Division of Molecular Biology and Clinical Genetics, Division of Biochemical and Molecular Diagnostics at University Hospital Cracow, and the Department of Forensic Medicine. These teams combine clinical service with basic research to advance genetic diagnostics and understand disease mechanisms, maintaining forensic genetics expertise developed over 20 years of practice.
